# A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

Source: https://onco.cc/trials/nct06969430/  
OnCo record `nct06969430` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Debio 1562M in acute myeloid leukaemia, run by Debiopharm International SA, now recruiting.

## Summary

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) is a phase 1/2 interventional study registered as NCT06969430 by Debiopharm International SA, with 154 participants planned, started 2025-05-30 and due to reach its primary completion in 2031-11. Interventions recorded: Debio 1562M.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06969430
- Phase: 1/2
- Setting: A Phase 1/2, First-in-human, Multicenter, Open-label Trial Evaluating the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
- Sponsor: Debiopharm International SA
- Enrolled: 154

## Sources

- ClinicalTrials.gov NCT06969430: https://clinicaltrials.gov/study/NCT06969430

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/)
- companies: [Debiopharm](https://onco.cc/companies/debiopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06969430.json